Product Information
CEFDINIR 250 MG/5 ML SUSP is a generic product labeled by Lupin Pharmaceuticals Inc., priced at $0.1100 per ML under NDC 68180072305. Its NADAC has been published 321 times since Aug 12, 2020.
FDA first approved this application on May 31, 2006. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
250 mg/5mL
Manufacturer
Lupin Pharmaceuticals Inc.NDC
68180072305
Classification
Generic
Dosage Form
POWDER, FOR SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CEFDINIRApproval Type
Generic (ANDA)
FDA Application
ANDA065259FDA Approved
5/31/2006
TE Code
AB
On Market Since
5/7/2007
Pharmacological Classes
Price Statistics
The NADAC for CEFDINIR 250 MG/5 ML SUSP has been published 321 times since Aug 12, 2020, and over the history we have for it it has declined 33.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1100 per ML |
|---|---|
| All-time high | $0.2195 (Apr 12, 2023) |
| All-time low | $0.1100 (Sep 23, 2026) |
| 52-week high | $0.1342 |
| 52-week low | $0.1100 |
| Median price | $0.1580 |
| Average price | $0.1542 |
| Largest weekly change | +47.5% (Mar 22, 2023) |
| Weeks tracked | 321 |
| Tracking since | Aug 12, 2020 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lupin Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Cefdinir market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cephalosporin Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CEFDINIR 250 MG/5 ML SUSP?
The current National Average Drug Acquisition Cost (NADAC) for CEFDINIR 250 MG/5 ML SUSP, manufactured by Lupin Pharmaceuticals Inc., is $0.1100 per ML (NDC 68180072305), effective Sep 30, 2026.
How has the price of CEFDINIR 250 MG/5 ML SUSP changed over time?
Over the history we have for it, the NADAC for CEFDINIR 250 MG/5 ML SUSP has declined 33.1%. It has been tracked across 321 weekly CMS publications since Aug 12, 2020.
What are the highest and lowest recorded NADAC prices for CEFDINIR 250 MG/5 ML SUSP?
Since Aug 12, 2020, the NADAC for CEFDINIR 250 MG/5 ML SUSP has ranged from a low of $0.1100 (Sep 23, 2026) to a high of $0.2195 (Apr 12, 2023), with a median of $0.1580 per ML.
Are there cheaper alternatives to CEFDINIR 250 MG/5 ML SUSP?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CEFDINIR 250 MG/5 ML SUSP in a comparable dosage form, but none are currently priced below it.
Who manufactures CEFDINIR 250 MG/5 ML SUSP?
CEFDINIR 250 MG/5 ML SUSP (NDC 68180072305) is labeled by Lupin Pharmaceuticals Inc., and CMS classifies it as a generic product.